REDWOOD CITY, Calif., July 13, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, and 24-month data from the SENZA Non-Surgical Refractory Back Pain (NSRBP) RCT will be presented at the American Society of Pain & Neuroscience (ASPN) Fifth Annual Conference to be held July 13-16, 2023 in Miami Beach, FL.
Nevro will also feature its HFX™ platform of SCS solutions in Exhibit Booth #223 and in a lunch symposium featuring Drs. Kasra Amirdelfan, Alexander Escobar, Usman Latif and Peter Pryzbylkowski. During the lunch symposium, presenters will highlight HFX iQ™, the first and only AI-based SCS system that learns from patients. It was developed to address the variability in pain from patient to patient and to help patients optimize and maintain long-term pain relief and improved quality of life.
Details for the abstract and lunch symposium presentations are below:
24-Month Durability of Pain Relief, Function, Quality of Life and Safety Outcomes for Non-Surgical Refractory Back Pain Patients with 10 kHz Spinal Cord
10 kHz SCS Provides Significant, Durable Pain Relief and Improved Lower Extremity Protective Sensation for Patients with Painful Diabetic Neuropathy
HFX iQ Lunch Symposium
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.59 |
| Daily Change: | -0.15 -4.01 |
| Daily Volume: | 551,734 |
| Market Cap: | US$134.520M |
November 18, 2024 November 12, 2024 November 11, 2024 October 29, 2024 September 24, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
